Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology

详细信息    查看全文

• 作者：J. de Castro (1)
  M. Cobo (2)
  D. Isla (3)
  J. Puente (4)
  N. Reguart (5)
  B. Cabeza (6)
  A. Gayete (7)
  M. S谩nchez (8)
  M. I. Torres (9)
  J. Ferreir贸s (6)
  
  1. Oncology Department ; La Paz University Hospital ; Paseo de la Castellana ; 261 ; 28046 ; Madrid ; Spain
  2. Oncology Department ; Carlos Haya Hospital ; M谩laga ; Spain
  3. Oncology Department ; Lozano Blesa Clinic Hospital ; Zaragoza ; Spain
  4. Oncology Department ; San Carlos Clinic Hospital ; Madrid ; Spain
  5. Oncology Department ; Clinic Hospital ; Barcelona ; Spain
  6. Radiology Department ; San Carlos Clinic Hospital ; Madrid ; Spain
  7. Radiology Department ; del Mar Hospital ; Barcelona ; Spain
  8. Radiology Department ; CDI ; Clinic Hospital ; Barcelona ; Spain
  9. Radiology Department ; La Paz University Hospital ; Madrid ; Spain
  
• 关键词：irRC ; Lung neoplasm ; MDCT ; Radiology report ; RECIST 1.1 ; TNM staging
• 刊名：Clinical and Translational Oncology
• 出版年：2015
• 出版时间：January 2015
• 年：2015
• 卷：17
• 期：1
• 页码：11-23
• 全文大小：1,361 KB
• 参考文献：1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC; 2012.
  2. Fraioli F, Anzidei M, Zaccagna F, Mennini ML, Serra G, Gori B, et al. Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience. Radiology. 2011;259:574鈥?2. CrossRef
  3. Yuan X, Zhang J, Quan C, Cao J, Ao G, Tian Y, et al. Differentiation of malignant and benign pulmonary nodules with first-pass dual-input perfusion CT. Eur Radiol. 2013;23:2469鈥?4. 2842-x" target="_blank" title="It opens in new window">CrossRef
  4. Baumueller S, Winklehner A, Karlo C, Goetti R, Flohr T, Russi EW, et al. Low-dose CT of the lung: potential value of iterative reconstructions. Eur Radiol. 2012;22:2597鈥?06. 2-2524-0" target="_blank" title="It opens in new window">CrossRef
  5. Lu GM, Zhao Y, Zhang LJ, Schoepf UJ. Dual-energy CT of the lung. AJR Am J Roentgenol. 2012;199:S40鈥?3. 2214/AJR.12.9112" target="_blank" title="It opens in new window">CrossRef
  6. Calzado Cantera A, Hern谩ndez-Gir贸n I, Salvad贸 Artells M, Rodr铆guez Gonz谩lez R. Estado actual y tendencia en el desarrollo tecnol贸gico para la reducci贸n de dosis en los equipos de tomograf铆a computarizada. Radiolog铆a. 2013;55:9鈥?6. 2013.08.004" target="_blank" title="It opens in new window">CrossRef
  7. Directiva 2013/59 Euratom del consejo de 5 de diciembre de 2013 por la que se establecen las normas de seguridad b谩sicas para la protecci贸n contra los peligros derivados de la exposici贸n a radiaciones ionizantes y se derogan las directivas 89/618 Euratom, 97/43 Euratom, 96/29 Euratom, 97/43 Euratom y 2003/122 Euratom. Art 60/61. Diario oficial de la uni贸n europea 17 de Enero 2014.
  8. Hurwitz LM, Reiman RE, Yoshizumi TT, Goodman PC, Toncheva G, Nguyen G, et al. Radiation dose from contemporary cardiothoracic multidetector CT protocols with an anthropomorphic female phantom: implications for cancer induction. Radiology. 2007;245:742鈥?0. 2453062046" target="_blank" title="It opens in new window">CrossRef
  9. Yilmaz MH, Albayram S, Yasar D, Ozer H, Adaletli I, Selcuk D, et al. Female breast radiation exposure during thorax multidetector computed tomography and the effectiveness of bismuth breast shield to reduce breast radiation dose. J Comput Assist Tomogr. 2007;31:138鈥?2. 235070.50055.e6" target="_blank" title="It opens in new window">CrossRef
  10. Chen MM, Coakley FV, Kaimal A, Laros RK Jr. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol. 2008;112:333鈥?0. CrossRef
  11. Pahade JK, Litmanovich D, Pedrosa I, Romero J, Bankier AA, Boiselle PM. Quality initiatives: imaging pregnant patients with suspected pulmonary embolism: what the radiologist needs to know. Radiographics. 2009;29:639鈥?4. 293085226" target="_blank" title="It opens in new window">CrossRef
  12. Dewachter P, Laroche D, Mouton-Faivre C, Bloch-Morot E, Cercueil JP, Metge L, et al. Immediate reactions following iodinated contrast media injection: a study of 38 cases. Eur J Radiol. 2011;77:495鈥?01. 2009.09.019" target="_blank" title="It opens in new window">CrossRef
  13. Liccardi G, Lobefalo G, Di Florio E, Di Iorio C, Occhiochiuso L, Romano L, et al. Strategies for the prevention of asthmatic, anaphylactic and anaphylactoid reactions during the administration of anesthetics and/or contrast media. J Investig Allergol Clin Immunol. 2008;18:1鈥?1.
  14. Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC. Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine premedication. AJR Am J Roentgenol. 2008;190:187鈥?0. 2214/AJR.07.2718" target="_blank" title="It opens in new window">CrossRef
  15. European Society of Urogenital Radiology (ESUR) guidelines on contrast media. 2014 delines/" class="a-plus-plus">http://www.esur.org/esur-guidelines/. Accessed May 2014.
  16. Alexopoulos E, Spargias K, Kyrzopoulos S, Manginas A, Pavlides G, Voudris V, et al. Contrast-induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic low-osmolar versus iso-osmolar contrast media. Am J Med Sci. 2010;339:25鈥?0. CrossRef
  17. Jost G, Pietsch H, Lengsfeld P, Hutter J, Sieber MA. The impact of the viscosity and osmolality of iodine contrast agents on renal elimination. Invest Radiol. 2010;45:255鈥?1. CrossRef
  18. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260鈥?1. CrossRef
  19. Nair A, Klusmann MJ, Jogeesvaran KH, Grubnic S, Green SJ, Vlahos I. Revisions to the TNM staging of non-small cell lung cancer: rationale, clinicoradiologic implications, and persistent limitations. Radiographics. 2011;31:215鈥?8. CrossRef
  20. Herth F, Ernst A, Schulz M, Becker H. Endobronchial ultrasound reliably differentiates between airway infiltration and compression by tumor. Chest. 2003;123:458鈥?2. 23.2.458" target="_blank" title="It opens in new window">CrossRef
  21. Fibla JJ, Cassivi SD, Brunelli A, Decker PA, Allen MS, Darling GE, et al. Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set. Lung Cancer. 2012;78:259鈥?2. 2012.09.010" target="_blank" title="It opens in new window">CrossRef
  22. Kawase A, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Visceral pleural invasion classification in non-small cell lung cancer. J Thorac Oncol. 2010;5:1784鈥?. CrossRef
  23. Glazer HS, Duncan-Meyer J, Aronberg DJ, Moran JF, Levitt RG, Sagel SS. Pleural and chest wall invasion in bronchogenic carcinoma: CT evaluation. Radiology. 1985;157:191鈥?. CrossRef
  24. Bandi V, Lunn W, Ernst A, Eberhardt R, Hoffmann H, Herth FJ. Ultrasound vs. CT in detecting chest wall invasion by tumor: a prospective study. Chest. 2008;133:881鈥?. CrossRef
  25. Barlesi F, Balleyguier C, Besse B, Bonodeau F, Brenac F, Corneloup O, et al. Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors. Ann Oncol. 2010;21:1682鈥?. CrossRef
  26. Glazer HS, Kaiser LR, Anderson DJ, Molina PL, Emami B, Roper CL, et al. Indeterminate mediastinal invasion in bronchogenic carcinoma: CT evaluation. Radiology. 1989;173:37鈥?2. 2781028" target="_blank" title="It opens in new window">CrossRef
  27. Herman SJ, Winton TL, Weisbrod GL, Towers MJ, Mentzer SJ. Mediastinal invasion by bronchogenic carcinoma: CT signs. Radiology. 1994;190:841鈥?. CrossRef
  28. Reck M, Barlesi F, Crino L, Henschke CI, Isla D, Stiebeler S, et al. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol. 2012;23:1111鈥?0. CrossRef
  29. de Langen AJ, Raijmakers P, Riphagen I, Paul MA, Hoekstra OS. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg. 2006;29:26鈥?. 2005.10.002" target="_blank" title="It opens in new window">CrossRef
  30. Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132:178S鈥?01S. CrossRef
  31. Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:568鈥?7. 2e" target="_blank" title="It opens in new window">CrossRef
  32. Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax. 2009;64:139鈥?3. 2008.100545" target="_blank" title="It opens in new window">CrossRef
  33. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228鈥?7. 2008.10.026" target="_blank" title="It opens in new window">CrossRef
  34. Wolchok JD, Hoos A, O鈥橠ay S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412鈥?0. 2.CCR-09-1624" target="_blank" title="It opens in new window">CrossRef
  35. Cervera Deval J. [RECIST and the radiologist]. Radiologia. 2014;56:193鈥?05.
  36. Chalian H, Tore HG, Horowitz JM, Salem R, Miller FH, Yaghmai V. Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0. Radiographics. 2011;31:2093鈥?05. CrossRef
  37. Lee HY, Lee KS, Ahn MJ, Hwang HS, Lee JW, Park K, et al. New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer. 2011;73:63鈥?. 2010.10.019" target="_blank" title="It opens in new window">CrossRef
  38. Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, et al. New response evaluation criteria in solid tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010;195:W221鈥?. 2214/AJR.09.3928" target="_blank" title="It opens in new window">CrossRef
  39. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010;195:281鈥?. 2214/AJR.09.4110" target="_blank" title="It opens in new window">CrossRef
  40. van Persijn van Meerten EL, Gelderblom H, Bloem JL. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol. 2010;20:1456鈥?7. CrossRef
  41. Yaghmai V, Miller FH, Rezai P, Benson AB 3rd, Salem R. Response to treatment series: part 2, tumor response assessment鈥搖sing new and conventional criteria. AJR Am J Roentgenol. 2011;197:18鈥?7. 2214/AJR.11.6581" target="_blank" title="It opens in new window">CrossRef
  42. Larici AR, del Ciello A, Maggi F, Santoro SI, Meduri B, Valentini V, et al. Lung abnormalities at multimodality imaging after radiation therapy for non-small cell lung cancer. Radiographics. 2011;31:771鈥?9. CrossRef
  43. Linda A, Trovo M, Bradley JD. Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes. Eur J Radiol. 2011;79:147鈥?4. 2009.10.029" target="_blank" title="It opens in new window">CrossRef
  44. Rodrigues G, Lock M, D鈥橲ouza D, Yu E, Van Dyk J. Prediction of radiation pneumonitis by dose鈥攙olume histogram parameters in lung cancer鈥揳 systematic review. Radiother Oncol. 2004;71:127鈥?8. 2004.02.015" target="_blank" title="It opens in new window">CrossRef
  45. Decker RH, Wilson LD. Advances in radiotherapy for lung cancer. Semin Respir Crit Care Med. 2008;29:285鈥?0. 2008-1076748" target="_blank" title="It opens in new window">CrossRef
  46. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev. 2009;35:309鈥?1. 2008.12.001" target="_blank" title="It opens in new window">CrossRef
  47. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004;22:4442鈥?. 200/JCO.2004.07.960" target="_blank" title="It opens in new window">CrossRef
  48. Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol. 2009;27:404鈥?0. 200/JCO.2008.16.2545" target="_blank" title="It opens in new window">CrossRef
  49. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753鈥?. 200/JCO.2006.07.3049" target="_blank" title="It opens in new window">CrossRef
  50. Lee HY, Lee KS, Hwang HS, Lee JW, Ahn MJ, Park K, et al. Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria. Korean J Radiol. 2010;11:618鈥?6. 2010.11.6.618" target="_blank" title="It opens in new window">CrossRef
  51. Miles KA, Lee TY, Goh V, Klotz E, Cuenod C, Bisdas S, et al. Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography. Eur Radiol. 2012;22:1430鈥?1. 2-2379-4" target="_blank" title="It opens in new window">CrossRef
  52. Li Y, Yang ZG, Chen TW, Chen HJ, Sun JY, Lu YR. Peripheral lung carcinoma: correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT. Lung Cancer. 2008;61:44鈥?3. 2007.10.021" target="_blank" title="It opens in new window">CrossRef
  53. Ma SH, Le HB, Jia BH, Wang ZX, Xiao ZW, Cheng XL, et al. Peripheral pulmonary nodules: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression. BMC Cancer. 2008;8:186. 2407-8-186" target="_blank" title="It opens in new window">CrossRef
  54. Spira D, Neumeister H, Spira SM, Hetzel J, Spengler W, von Weyhern CH, et al. Assessment of tumor vascularity in lung cancer using volume perfusion CT (VPCT) with histopathologic comparison: a further step toward an individualized tumor characterization. J Comput Assist Tomogr. 2013;37:15鈥?1. 277c84f" target="_blank" title="It opens in new window">CrossRef
  55. Tacelli N, Remy-Jardin M, Copin MC, Scherpereel A, Mensier E, Jaillard S, et al. Assessment of non-small cell lung cancer perfusion: pathologic-CT correlation in 15 patients. Radiology. 2010;257:863鈥?1. CrossRef
  56. Fraioli F, Anzidei M, Serra G, Liberali S, Fiorelli A, Zaccagna F, et al. Whole-tumour CT-perfusion of unresectable lung cancer for the monitoring of anti-angiogenetic chemotherapy effects. Br J Radiol. 2013;86:20120174. 259/bjr.20120174" target="_blank" title="It opens in new window">CrossRef
  57. Lind JS, Meijerink MR, Dingemans AM, van Kuijk C, Ollers MC, de Ruysscher D, et al. Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol. 2010;20:2890鈥?. CrossRef
  58. Tacelli N, Santangelo T, Scherpereel A, Duhamel A, Deken V, Klotz E, et al. Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy. Eur Radiol. 2013;23:2127鈥?6. 2821-2" target="_blank" title="It opens in new window">CrossRef
  59. NCCN clinical practice guidelines in oncology (NCCN Guidelines^庐). Non-small cell lung cancer. Version 3. 2014. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed May 2014.
  60. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii56鈥?4.
  
• 刊物主题：Oncology;
• 出版者：Springer Milan
• ISSN：1699-3055

文摘

The last decade has seen substantial progress in the diagnostic and therapeutic approach to lung cancer, thus meaning that its prognosis has improved. The Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology have therefore produced a national consensus statement to make recommendations for radiological diagnosis and assessment of treatment response in patients with lung cancer. This expert group recommends multi-detector computed tomography as the technique of choice for investigating this disease. The radiology report should include a full assessment by the TNM staging system. Lastly, when the patient is on immunotherapy, response evaluation should employ not only response evaluation criteria in solid tumours, but also immune-related response criteria.